CAG
HAE icon

Csenge Advisory Group’s Haemonetics HAE Stock Holding History

Csenge Advisory Group’s Portfolio HAE Stock Details HAE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-6,553
Closed -$587K – 685
2023
Q3 		$587K Buy
+6,553
New +$585K 0.04% 333
2018
Q4 		– Sell
-12
Closed -$1K – 708
2018
Q3 		$1K Buy
+12
New +$1.24K ﹤0.01% 868

Other funds holding HAE

Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Csenge Advisory Group's HAE Position: Q4 2023 in Review

Csenge Advisory Group sold out of Haemonetics (HAE) in Q4 2023, closing a stake of 6,553 shares — an estimated $587K sold.

Csenge Advisory Group first reported a position in HAE in Q3 2018 and held it in 2 quarters. The position peaked at $587K in Q3 2023. 295 funds tracked by Wall St. Rank hold HAE as of Q4 2023.

  • Csenge Advisory Group reported no remaining Haemonetics position as of Q4 2023 after selling out during the quarter.
  • Csenge Advisory Group sold 6,553 Haemonetics shares in Q4 2023, an estimated $587K.
  • Csenge Advisory Group first reported a position in Haemonetics in Q3 2018 and held it in 2 quarters.
  • Csenge Advisory Group's Haemonetics position peaked at $587K in Q3 2023.
  • 295 funds tracked by Wall St. Rank held Haemonetics as of Q4 2023.

Based on Csenge Advisory Group's 13F filing for Q4 2023, filed 13 Feb 2024.